Quantitative changes of melanoma-associated antigens as a biomarker for targeted therapy response

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F16%3AN0000192" target="_blank" >RIV/00064173:_____/16:N0000192 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/16:43911791

Result on the web

<a href="http://dx.doi.org/10.1111/exd.12947" target="_blank" >http://dx.doi.org/10.1111/exd.12947</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/exd.12947" target="_blank" >10.1111/exd.12947</a>

Result language

angličtina

Original language name

Quantitative changes of melanoma-associated antigens as a biomarker for targeted therapy response

Original language description

Novel treatment modalities significantly improve survival of patients with metastatic melanoma. However, targeted therapy with BRAF inhibitors is connected with development of drug resistance within 6-9 months. Biomarkers for prediction of treatment response and failure are indispensably needed. Here we determine the prognostic impact of multimarker detection of circulating melanoma cells in patients with metastatic melanoma treated with vemurafenib. In this prospective study, 51 patients with metastatic melanoma in unresectable stage III and metastatic stage IV treated with vemurafenib were included. The real-time RT-PCR values of 5 melanoma markers Melan-A, gp100, MAGE-3, MIA, and ABCB5 prior to the treatment and within the therapy were compared to the data collected after the melanoma surgery. Longitudinal follow-up of melanoma markers in patients treated with vemurafenib correlates with prognostic parameters such as progression free survival and overall survival. A rapid drop of markers > 50 % within 4 weeks of treatment was associated with long-term response to therapy. Elevation of tumor markers precedes clinical progression and may give an early warning of development of drug resistance. Melanoma circulating cells hold the potential as a prognostic, predictive, and pharmacodynamic biomarker during the treatment with vemurafenib.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FO - Dermatology and venereology

OECD FORD branch

—

Project

<a href="/en/project/NT14440" target="_blank" >NT14440: Detection of circulating melanoma cells for evaluation of immunotherapeutic effect</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Experimental Dermatology

ISSN

0906-6705

e-ISSN

—

Volume of the periodical

25

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

3

Pages from-to

727-729

UT code for WoS article

000385353200001

EID of the result in the Scopus database

2-s2.0-84983512690